In contrast, a combined regimen of 2 μM AF plus and the proteasome inhibitor (PI), bortezomib (Bz), or TrxR1 knockdown plus Bz induced paraptosis selectively in breast cancer cells, sparing MCF10A cells. Here, TXNRD1 is linked to breast carcinoma.